Alps Advisors Inc Adc Therapeutics Sa Transaction History

Alps Advisors Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$4.66 - $10.31 $32,582 - $72,087	-6,992 Reduced 15.35%	38,571 $186,000
Q2 2022 Aug 11, 2022	SELL	$5.96 - $14.99 $198,360 - $498,897	-33,282 Reduced 42.21%	45,563 $362,000
Q1 2022 May 16, 2022	SELL	$13.28 - $20.03 $132,056 - $199,178	-9,944 Reduced 11.2%	78,845 $1.16 Million
Q4 2021 Feb 09, 2022	SELL	$19.29 - $31.51 $101,176 - $165,269	-5,245 Reduced 5.58%	88,789 $1.79 Million
Q3 2021 Nov 15, 2021	SELL	$20.45 - $30.0 $129,284 - $189,660	-6,322 Reduced 6.3%	94,034 $2.55 Million
Q2 2021 Aug 11, 2021	BUY	$20.38 - $27.04 $2.05 Million - $2.71 Million	100,356 New	100,356 $2.44 Million

55.1M

82.7K

31.5K

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $270M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.